胎脾LAK细胞与重组白细胞介素-2在病人体内的联合应用

Combining Administration of Allogeneic LAK Cells from Human Fetal Spleens and Recombinant Interleukin-2 to Cancer Patients

自体LAK细胞用于临床治疗肿瘤病人已收到一定疗效。但是在实施此疗法过程中存在一个难题,即LAK细胞数量问题。

We have investigated the antitumor activity of LAK cells induced from human fetal spleens in the presence of rIL-2 and the frequencies of their precurser cells. Now the clinical application of fetal LAK cells was reported. Three cancer patients who had received surgical resection of their primary lesions were treated with the combining administration of fetal LAK cells and rIL-2. RIL-2 was administered 6 days(25×10~5U/day)iv or 10 days(5×10~4U/day)ip befor and after the transfer of fetal LAK cells. Of 3 cases, only one case appeared temporary low fever. No other toxicity was observed. The results indicated that the combining administration of fetal LAK cells and rIL-2 to cancer patients was safe and feasible